“One treatment a year. Life changing.”
Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally invasive delivery.
This unique combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular cancers.
Location: United Kingdom, England, Oxford
Employees: 11-50
Total raised: $37M
Founded date: 2014
Investors 3
| Date | Name | Website |
| - | NeoMed Man... | neomed.net... |
| - | V-Bio Vent... | v-bio.vent... |
| - | Forbion | forbion.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.03.2021 | Series B | $37M | Forbion |
Mentions in press and media 4
| Date | Title | Description | Source |
| 07.06.2021 | Oxular appoints Dr. Friedrich Asmus as Chief Medical Officer | OXFORD, England , June 7, 2021 /PRNewswire/ -- Oxular Limited, a leading retinal therapeutics develo... | marketscre... |
| 01.03.2021 | Oxular Ltd - Oxular raises $37 million | Led by specialist life sciences investor, Forbion Investment will fund Phase 2 human clinical s... | ipgroupplc... |
| 01.03.2021 | Forbion leads $37M financing for Oxular | Investment will fund Phase 2 human clinical studies evaluating Oxular’s 12-month treatment for diabe... | forbion.co... |
| 01.03.2021 | Oxular raises $37 million | Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announced that ... | neomed.net... |